[Synergistic therapeutic effect of adriamycin with 5-fluor-uracil, with prednisolon and with cyclophosphamide on chemically induced mammary cancer of the rat (author's transl)].
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002330:Carmustine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy*; D008727:Methotrexate / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D051381:Rats; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D015127:9,10-Dimethyl-1,2-benzanthracene; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D005472:Fluorouracil; D002330:Carmustine; D008727:Methotrexate
Synergismus von Adriamycin mit 5-Fluor-Uracil, mit Prednisolon und mit Cyclophosphamid am autochthonen Mammacarcinom der Ratte.